135 related articles for article (PubMed ID: 38103361)
1. TERT promoter mutations and the outcome of patients with advanced urothelial carcinoma treated by platinum-based chemotherapy or pembrolizumab.
Mollica V; Tassinari E; Santoni M; Marchese PV; Giunchi F; Maloberti T; Tateo V; Ricci C; Rosellini M; Marchetti A; Fiorentino M; Biase D; Massari F
Pathol Res Pract; 2024 Jan; 253():155008. PubMed ID: 38103361
[TBL] [Abstract][Full Text] [Related]
2. A hypothesis-generating analysis on the role of TERT promoter mutation in advanced urothelial carcinoma treated with immunotherapy.
Marchese PV; Mollica V; De Biase D; Giunchi F; Tassinari E; Marchetti A; Rosellini M; Nuvola G; Maloberti T; Fiorentino M; Massari F
Pathol Res Pract; 2022 Aug; 236():153983. PubMed ID: 35751929
[TBL] [Abstract][Full Text] [Related]
3. Pembrolizumab versus chemotherapy in recurrent, advanced urothelial cancer in Japanese patients: a subgroup analysis of the phase 3 KEYNOTE-045 trial.
Nishiyama H; Yamamoto Y; Sassa N; Nishimura K; Fujimoto K; Fukasawa S; Yokoyama M; Enokida H; Takahashi K; Tanaka Y; Imai K; Shimamoto T; Perini R; Frenkl T; Bajorin D; Bellmunt J
Int J Clin Oncol; 2020 Jan; 25(1):165-174. PubMed ID: 31729625
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of Pembrolizumab as Second-line Therapy for the Treatment of Locally Advanced or Metastatic Urothelial Carcinoma in Sweden.
Srivastava T; Prabhu VS; Li H; Xu R; Zarabi N; Zhong Y; Pellissier JM; Perini RF; de Wit R; Mamtani R
Eur Urol Oncol; 2020 Oct; 3(5):663-670. PubMed ID: 31412001
[TBL] [Abstract][Full Text] [Related]
5. Fibroblast Growth Factor Receptor 3 Alteration Status is Associated with Differential Sensitivity to Platinum-based Chemotherapy in Locally Advanced and Metastatic Urothelial Carcinoma.
Teo MY; Mota JM; Whiting KA; Li HA; Funt SA; Lee CH; Solit DB; Al-Ahmadie H; Milowsky MI; Balar AV; Pietzak E; Dalbagni G; Bochner BH; Ostrovnaya I; Bajorin DF; Rosenberg JE; Iyer G
Eur Urol; 2020 Dec; 78(6):907-915. PubMed ID: 32753285
[TBL] [Abstract][Full Text] [Related]
6. Significance of second progression-free survival in patients with advanced urothelial cancer who received platinum-based combination chemotherapy followed by pembrolizumab.
Sato R; Inamoto T; Matsushita Y; Takemura A; Uchimoto T; Sano A; Tanaka H; Ishikawa G; Watanabe K; Watanabe H; Tamura K; Motoyama D; Sugiyama T; Otsuka A; Harada KI; Azuma H; Miyake H
Int J Urol; 2023 Sep; 30(9):730-736. PubMed ID: 36575640
[TBL] [Abstract][Full Text] [Related]
7.
Liu T; Li S; Xia C; Xu D
Front Immunol; 2022; 13():1071390. PubMed ID: 36713366
[TBL] [Abstract][Full Text] [Related]
8. Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials.
Bellmunt J; de Wit R; Fradet Y; Climent MA; Petrylak DP; Lee JL; Fong L; Necchi A; Sternberg CN; O'Donnell PH; Powles T; Plimack ER; Bajorin DF; Balar AV; Castellano D; Choueiri TK; Culine S; Gerritsen W; Gurney H; Quinn DI; Vuky J; Vogelzang NJ; Cristescu R; Lunceford J; Saadatpour A; Loboda A; Ma J; Rajasagi M; Godwin JL; Homet Moreno B; Grivas P
Clin Cancer Res; 2022 May; 28(10):2050-2060. PubMed ID: 35247908
[TBL] [Abstract][Full Text] [Related]
9. Bone targeting agents, but not radiation therapy, improves survival in patients with bone metastases from advanced urothelial carcinoma receiving pembrolizumab: results from the ARON-2 study.
Santoni M; Massari F; Takeshita H; Tapia JC; Dionese M; Pichler R; Rizzo M; Lam ET; Grande E; Kemp R; Molina-Cerrillo J; Calabrò F; Tural D; Küronya Z; Kucharz J; Fiala O; Seront E; Kopp RM; Abahssain H; Kopecky J; Martignetti A; Kanesvaran R; Zakopoulou R; Ansari J; Landmesser J; Mollica V; Porta C; Bellmunt J; Salah S; Santini D
Clin Exp Med; 2023 Dec; 23(8):5413-5422. PubMed ID: 37917218
[TBL] [Abstract][Full Text] [Related]
10. Clinical Benefit of Pembrolizumab in Advanced Urothelial Cancer Patients in Real-Life Setting: An Efficacy and Safety Monocentric Study.
Dang E; Vallée A; Lepage-Seydoux C; Sejean K; Bonan B; Abraham C; Beuzeboc P; Ratta R
Curr Oncol; 2022 Feb; 29(2):945-955. PubMed ID: 35200579
[TBL] [Abstract][Full Text] [Related]
11. Small-cell Carcinomas of the Urinary Bladder and Prostate: TERT Promoter Mutation Status Differentiates Sites of Malignancy and Provides Evidence of Common Clonality Between Small-cell Carcinoma of the Urinary Bladder and Urothelial Carcinoma.
Priemer DS; Wang M; Zhang S; Lopez-Beltran A; Kouba E; Montironi R; Davidson DD; MacLennan GT; Wang L; Osunkoya AO; Deng Y; Emerson RE; Cheng L
Eur Urol Focus; 2018 Dec; 4(6):880-888. PubMed ID: 28753872
[TBL] [Abstract][Full Text] [Related]
12. High prevalence of TERT promoter mutations in micropapillary urothelial carcinoma.
Nguyen D; Taheri D; Springer S; Cowan M; Guner G; Mendoza Rodriguez MA; Wang Y; Kinde I; VandenBussche CJ; Olson MT; Ricardo BF; Cunha I; Fujita K; Ertoy D; Kinzler KW; Bivalacqua TJ; Papadopoulos N; Vogelstein B; Netto GJ
Virchows Arch; 2016 Oct; 469(4):427-34. PubMed ID: 27520411
[TBL] [Abstract][Full Text] [Related]
13. Pembrolizumab monotherapy versus chemotherapy for treatment of advanced urothelial carcinoma with disease progression during or following platinum-containing chemotherapy. A Cochrane Rapid Review.
Narayan V; Kahlmeyer A; Dahm P; Skoetz N; Risk MC; Bongiorno C; Patel N; Hwang EC; Jung JH; Gartlehner G; Kunath F
Cochrane Database Syst Rev; 2018 Jul; 7(7):CD012838. PubMed ID: 30036453
[TBL] [Abstract][Full Text] [Related]
14. Enfortumab vedotin versus platinum rechallenge in post-platinum, post-pembrolizumab advanced urothelial carcinoma: A multicenter propensity score-matched study.
Taguchi S; Kawai T; Ambe Y; Kishitani K; Sugimoto K; Miyakawa J; Nakamura Y; Noda M; Kaneko T; Kamei J; Obinata D; Yamaguchi K; Kakutani S; Furuya Y; Sato Y; Uemura Y; Akiyama Y; Yamada Y; Sato Y; Yamada D; Enomoto Y; Nishimatsu H; Fujimura T; Fukuhara H; Nakagawa T; Takahashi S; Kume H
Int J Urol; 2023 Dec; 30(12):1180-1186. PubMed ID: 37740409
[TBL] [Abstract][Full Text] [Related]
15. Optimal Timing of Switching from Platinum-based Chemotherapy to Pembrolizumab for Advanced Urothelial Carcinoma Based on Real-world Data: A Multi-institutional Retrospective Study.
Furubayashi N; Morokuma F; Tomoda T; Hori Y; Negishi T; Miura A; Komori H; Kuroiwa K; Nakamura M
Anticancer Res; 2022 Mar; 42(3):1571-1577. PubMed ID: 35220254
[TBL] [Abstract][Full Text] [Related]
16. Clinical Outcomes of Mixed Response to Pembrolizumab in Advanced Urothelial Carcinoma After Platinum-based Chemotherapy.
Furubayashi N; Negishi T; Sakamoto N; Tamura S; Morokuma F; Song Y; Hori Y; Tomoda T; Seki N; Kuroiwa K; Nakamura M
In Vivo; 2021; 35(5):2869-2874. PubMed ID: 34410980
[TBL] [Abstract][Full Text] [Related]
17. Avelumab as second-line therapy for metastatic, platinum-treated urothelial carcinoma in the phase Ib JAVELIN Solid Tumor study: 2-year updated efficacy and safety analysis.
Apolo AB; Ellerton JA; Infante JR; Agrawal M; Gordon MS; Aljumaily R; Gourdin T; Dirix L; Lee KW; Taylor MH; Schöffski P; Wang D; Ravaud A; Manitz J; Pennock G; Ruisi M; Gulley JL; Patel MR
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33037118
[TBL] [Abstract][Full Text] [Related]
18. Targeted sequencing of plasmacytoid urothelial carcinoma reveals frequent TERT promoter mutations.
Palsgrove DN; Taheri D; Springer SU; Cowan M; Guner G; Mendoza Rodriguez MA; Rodriguez Pena MDC; Wang Y; Kinde I; Ricardo BFP; Cunha I; Fujita K; Ertoy D; Kinzler KW; Bivalacqua TJ; Papadopoulos N; Vogelstein B; Netto GJ
Hum Pathol; 2019 Mar; 85():1-9. PubMed ID: 30447301
[TBL] [Abstract][Full Text] [Related]
19. The pretreatment neutrophil-to-lymphocyte ratio is a novel biomarker for predicting clinical responses to pembrolizumab in platinum-resistant metastatic urothelial carcinoma patients.
Ogihara K; Kikuchi E; Shigeta K; Okabe T; Hattori S; Yamashita R; Yoshimine S; Shirotake S; Nakazawa R; Matsumoto K; Mizuno R; Hara S; Oyama M; Masuda T; Niwakawa M; Oya M
Urol Oncol; 2020 Jun; 38(6):602.e1-602.e10. PubMed ID: 32139290
[TBL] [Abstract][Full Text] [Related]
20. Impact of the objective response to and number of cycles of platinum-based first-line chemotherapy for metastatic urothelial carcinoma on overall survival of patients treated with pembrolizumab.
Kato M; Kobayashi T; Matsui Y; Ito K; Hikami K; Yamada T; Ogawa K; Nakamura K; Sassa N; Yokomizo A; Abe T; Tsuchihashi K; Tatarano S; Inokuchi J; Tomida R; Fujiwara M; Takahashi A; Matsumoto K; Shimizu K; Araki H; Kurahashi R; Ozaki Y; Tashiro Y; Uegaki M; Kojima T; Uchida J; Ogawa O; Nishiyama H; Kitamura H;
Int J Urol; 2021 Dec; 28(12):1261-1267. PubMed ID: 34545627
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]